Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon

Rheumatology

Volumn 44, Issue 4, 2005, Pages 488-494

  Furspan, P B ^a   Chatterjee, S ^b   Mayes, M D ^c   Freedman, R R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Cooling; Endothelium; Raynaud's phenomenon; Scleroderma; Signal transduction; Vascular smooth muscle; Vasospasm

Indexed keywords

ACETYLCHOLINE; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR STIMULATING AGENT; CISAPRIDE; DIURETIC AGENT; GEMFIBROZIL; GENISTEIN; LANSOPRAZOLE; LEVOTHYROXINE; METHOTREXATE; NIFEDIPINE; NORADRENALIN; OMEPRAZOLE; PENTOXIFYLLINE; PILOCARPINE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; THYROID HORMONE; TRIAMTERENE; TYRPHOSTIN; VANADATE SODIUM; ENZYME INHIBITOR;

ADULT; ARTERIOLE; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTERY DILATATION; ARTERY PERFUSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COOLING; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; ISOLATION PROCEDURE; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAYNAUD PHENOMENON; SCLERODERMA; SKIN BIOPSY; SKIN BLOOD VESSEL; STATISTICAL SIGNIFICANCE; TEMPERATURE MEASUREMENT; COLD; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHOSPHORYLATION; SKIN; SYSTEMIC SCLEROSIS; VASCULARIZATION; VASOCONSTRICTION;

ADULT; ARTERIOLES; COLD; ENZYME INHIBITORS; FEMALE; GENISTEIN; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; VASOCONSTRICTION;

EID: 18744363909     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh517     Document Type: Article

References (36)

1. Wagerle LC, Kim SJ, Russo P. Protein tyrosine kinase signaling in cold-stimulated contraction of newborn lamb cerebral arteries. Am J Physiol 1996;270:H645-50.
2. Furspan PB, Freedman RR. Effect of modulators of protein tyrosine kinase activity on gender-related differences in vascular reactivity at reduced temperature. J Cardiovasc Pharmacol 1998;32:728-35.
3. Dahdah NS, Russo P, Wagerle LC. Phosphorylation in coronary artery cold-induced contraction in the newborn lamb. Cryobiology 2001;42:40-8.
4. Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 2004;50:1578-85.
5. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
6. Ingemansson R, Budrikis A, Bolys R, Sjoberg T, Steen S. Effect of temperature in long-term preservation of vascular endothelial and smooth muscle function. Ann Thorac Surg 1996;61:1413-7.
7. Iwaki H, Sakamoto A, Tanaka S. Effects of temperature and preservation time on the pharmacological response of isolated vascular endothelial and smooth muscle function. Nippon Ika Daigaku Zasshi 1999;66:15-20.
8. Flavahan NA, Flavahan S, Liu Q et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000;43:1886-90.
9. Murphy TV, Spurrell BE, Hill MA. Tyrosine phosphorylation following alterations in arteriolar intraluminal pressure and wall tension. Am J Physiol Heart Circ Physiol 2001;281:H1047-56.
10. Furspan PB, Mayes MD, Freedman RR. Effect of temperature and modulators of protein tyrosine kinase activity on the reactivity of isolated venules in secondary Raynaud's phenomenon. J Rheumatol 2001;28:2263-8.
11. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:H586-92.
12. Moritoki H, Hisayama T, Takeuchi S, Kondoh W, Takeji Y. Possible involvement of tyrosine kinase in the LPS-promoted initiation of L-arginine-induced relaxation of rat aorta mediated by induction of no synthase. Life Sci 1995;57:L125-30.
13. Yamawaki H, Sato K, Hori M, Ozaki H, Karaki H. Platelet-derived growth factor causes endothelium-independent relaxation of rabbit mesenteric artery via the release of a prostanoid. Br J Pharmacol 2000;131:1546-52.
14. Andersen GN, Mincheva-Nilsson L, Kazzam E et al. Assessment of vascular function in systemic sclerosis: Indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 2002;46:1324-32.
15. Hejtmancik M Jr, Su C. Segmental variation of adrenergic innervation in rabbit mesenteric vasculature. J Cardiovasc Pharmacol 1981;3: 1141-51.
16. Susol E, MacGregor AJ, Barrett JH et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000;43:1641-6.
17. Fagundus DM, Leroy EC. Cytokines and systemic sclerosis. Clin Dermatol 1994;12:407-17.
18. Gay S, Jones RE Jr, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sisoncogene expression in scleroderma. J Invest Dermatol 1989;92:301-3.
19. Sauro MD, Thomas B. Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s). J Pharmacol Exp Ther 1993;267: 1119-25.
20. 2+ in rabbit isolated ear artery by platelet-derived growth factor. Br J Pharmacol 1995; 114:138-42.
21. Bouillier H, Samain E, Miserey S et al. Transforming growth factor-beta1 modulates angiotensin II-induced calcium release in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2000;18:733-42.
22. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
23. Romero LI, Pincus SH. In situ localization of interleukin-6 in normal skin and atrophic cutaneous disease. Int Arch Allergy Immunol 1992;99:44-9.
24. Murakami M, Hibi M, Nakagawa N et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993;260:1808-10.
25. Neumann C, Zehentmaier G, Danhauser-Riedl S, Emmerich B, Hallek M. Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1. Eur J Immunol 1996;26: 379-84.
26. Guschin D, Rogers N, Briscoe J et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J 1995;14:1421-9.
27. Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL. Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992;65:278-85.
28. Ito A, Shimokawa H, Kadokami T et al. Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1 beta in pigs in vivo. J Clin Invest 1995;96:1288-94.
29. White CR, Haidekker MA, Stevens HY, Frangos JA. Extracellular signal-regulated kinase activation and endothelin-1 production in human endothelial cells exposed to vibration. J Physiol (Lond) 2004;555:565-72.
30. Freedman RR, Girgis R, Mayes MD. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 1999;26:2386-8.
31. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998; 37:1188-92.
32. Andersen GN, Caidahl K, Kazzam E et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: Findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000;43:1085-93.
33. Kahaleh MB. Vascular disease in scleroderma. Endothelial T lymphocyte-fibroblast interactions. Rheum Dis Clin North Am 1990;16:53-73.
34. Simonini G, Pignone A, Generini S et al. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 2000;155:1-15.
35. Ringqvist A, Jonason T, Leppert J, Ringqvist I. Non-invasive investigation of endothelium-dependent dilatation of the brachial artery in women with primary Raynaud's phenomenon. Clin Sci (Colch) 1998;94:239-43.
36. Smyth AE, Bell AL, Bruce IN, McGrann S, Allen JA. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis 2000;59: 870-4.